Recordati

Equities

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana 12:44:59 2024-03-28 pm EDT 5-day change 1st Jan Change
51.24 EUR -0.97% Intraday chart for Recordati -0.27% +4.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stock exchanges without momentum in opening; banking sluggish AN
Recordati buys back own shares for more than EUR1 million AN
Indexes up; Leonardo tops on Mib. AN
Futures directionless on Fed day AN
Recordati has bought back its own shares for more than EUR1 million AN
Mib queen of Europe, focus shifts to Fed AN
Recordati proposes dividend after revenue and profit growth AN
Mib veers bullish; Brembo to fourth bullish AN
Recordati bought back 14,103 of its own shares for more than EUR730,000 AN
Recordati has bought back more than 32,000 of its own ordinary shares AN
Mib at peak since 2008; MPS updates annual max AN
Recordati has purchased treasury shares for more than EUR560,000 AN
Europeans heading for a slightly down opening AN
Milan maglia rosa; gas prices fall sharply AN
Futures up; property crisis continues in China AN
Italy's Recordati says Red Sea attacks not affecting its output RE
World stock exchanges set record highs; Tenaris leads on Mib. AN
Recordati Industria Chimica e Farmaceutica S.p.A. Provides Revenue Guidance for the Year 2024 and 2025 CI
Transcript : Recordati Industria Chimica e Farmaceutica S.p.A., 2023 Earnings Call, Feb 22, 2024
Recordati to Pursue Further Talks with US FDA on Development of Neuroblastoma Treatment MT
Recordati Forecasts Continued Growth in Net Revenue, Adjusted Net Income in FY24 MT
Recordati closes 2023 with growing revenues and profits AN
Stock markets bullish; record accounts for Tenaris AN
Futures bullish; Nvidia with record numbers AN
Recordati Industria Chimica e Farmaceutica S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chart Recordati
More charts
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (32.1%). Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
51.24 EUR
Average target price
50.84 EUR
Spread / Average Target
-0.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Recordati - Borsa Italiana
  4. News Recordati
  5. Recordati Expects FY21 Results to Hit Lower End of Guidance Range